-
Mashup Score: 0Exciting research in CTCL: genomics, the tumor microenvironment and the potential role of MRD - 8 month(s) ago
Pierluigi Porcu, MD, Jefferson Health, Sidney Kimmel Cancer Center, Philadelphia, PA, discusses ongoing research in the field of cutaneous T-cell lymphoma (CTCL). Dr Porcu highlights several interesting areas being explored, including genomic research using single-cell analysis, the tumor microenvironment, and studies exploring the potential role of MRD as a strategy to redefine disease stage. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjhemonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Blood Cancer Talks: Management of Newly Diagnosed Hodgkin's Lymphoma on Apple Podcasts - 10 month(s) ago
Show Blood Cancer Talks, Ep Management of Newly Diagnosed Hodgkin’s Lymphoma – Jul 15, 2023
Source: Apple PodcastsCategories: Latest Headlines, Partners & KOLsTweet-
📢 Our latest episode on Hodgkin's Lymphoma is out now! Join us as we dive deep into the history of frontline treatment in young/fit pts with HL with the incredible Dr. Nancy Bartlett! We also discuss 3 🔥 trials #ASCO23 #ICML2023 S1826 HD21 FIL-ROUGE https://t.co/GJpjeb3Mez https://t.co/YN6gboP4KR
-
-
Mashup Score: 0Data Support Liso-Cel for Relapsed or Refractory CLL/SLL - 11 month(s) ago
New research suggests that lisocabtagene maraleucel (liso-cel) is a potential treatment option for relapsed or refractory CLL/SLL.
Source: Cancer Therapy AdvisorCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Liso-cel is a potential treatment option for patients with R/R chronic lymphocytic #leukemia/small lymphocytic #lymphoma. Presented at the @icmlugano #ICML2023. https://t.co/Oxc42JMFjh #CLL #SLL
-
-
Mashup Score: 1Intensified ABVD Bests PET-Adapted ABVD as First-Line Therapy for Hodgkin Lymphoma - 11 month(s) ago
Intensified ABVD can improve outcomes, when compared with PET-adapted ABVD, in patients with previously untreated Hodgkin lymphoma, a phase 3 study suggests.
Source: Cancer Therapy AdvisorCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Intensified doxorubicin, bleomycin, vinblastine, and dacarbazine can improve outcomes, when compared with PET-adapted ABVD, in patients with previously untreated #HodgkinLymphoma. Presented at the @icmlugano #ICML2023. https://t.co/1zzwXOVS4D
-
-
Mashup Score: 0Risk-Adapted Treatment Approach Produces Durable Remissions in MCL - 11 month(s) ago
A risk-adapted treatment approach can produce durable responses in younger patients with mantle cell lymphoma, a phase 2 trial suggests.
Source: Cancer Therapy AdvisorCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
A risk-adapted treatment approach can produce durable responses in younger patients with #mantleCellLymphoma. Presented at @icmlconf #ICML2023. https://t.co/qKD5vKofhC #MCL #lymphoma
-
-
Mashup Score: 1CLAVES en Linfoma del Manto: ensayo fase 2 WINDOW-2 - 11 month(s) ago
Eva González Barca, del Instituto Catalán de Oncología Hospitalet – Hospital Duran i Reynals, analiza las principales líneas estratégicas y conclusiones del …
Source: YouTubeCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @sehh_es: #ICML2023 #EHA2023 CLAVES en Linfoma del Manto Ensayo fase 2 WINDOW-2 https://t.co/KXhloTbVfU a través de @YouTube https://t.c…
-
Dr. Pierluigi Porcu talked to @VJHemOnc at @icmlconf about the latest in cutaneous T-cell lymphoma #CTCL, including genomics, the tumor microenvironment, and the potential role of MRD as a strategy to redefine disease stage #ICML2023 https://t.co/FWJxH5DIpp